Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Ascentage Pharma Group International ( (HK:6855) ).
Ascentage Pharma will present data from six clinical studies involving three key drug candidates at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, underscoring the company’s growing presence in cutting-edge cancer research. Three of the selected abstracts are rapid oral presentations and three are poster presentations, highlighting the clinical potential of its targeted therapies in both adult hematologic cancers and pediatric solid tumors.
Two of the rapid oral presentations will feature Olverembatinib, including its use in combination with blinatumomab for advanced leukemia and updated efficacy and safety data as a second-line therapy in chronic-phase chronic myeloid leukemia. A third rapid oral presentation will cover Alrizomadlin alone or with Lisaftoclax in pediatric patients with relapsed or metastatic rhabdomyosarcoma and other soft-tissue sarcomas, potentially strengthening Ascentage Pharma’s positioning in both hematology and pediatric oncology segments.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$93.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a Hong Kong–listed biopharmaceutical company focused on developing innovative oncology therapies. Its leading products include Olverembatinib, the first third-generation BCR-ABL inhibitor approved in China, Lisaftoclax, a China-developed Bcl-2 selective inhibitor, and Alrizomadlin, an MDM2-p53 inhibitor, targeting hematologic malignancies and solid tumors in global markets.
Average Trading Volume: 2,073,352
Technical Sentiment Signal: Buy
Current Market Cap: HK$19.67B
For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.